Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Dividend ETFs remain popular among investors looking for steady income and long-term stability, especially in uncertain markets. Using TipRanks’ Va...

VYMI vs. VIG vs. VYM: Which Vanguard Dividend ETF Pays the Highest Income?

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on May 8 and set a price target of CHF135.00. The company’s shares closed...

Kepler Capital  Remains a Buy on Novartis AG (NOVN)

Envista Holdings (($NVST)) has held its Q1 earnings call. Read on for the main highlights of the call. Envista Holdings’ latest earnings call struc...

Envista Holdings Signals Confidence Despite Tariff and China Risks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Qiagen (QGEN), Perrigo Company (PRGO) and Envista Ho...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Dividend investing is an easy way to earn regular income. Many investors choose steady dividend-paying companies, and Vanguard ETFs offer a low-cos...

3 Best Vanguard ETFs Investors Are Using for Stable Dividend Income in 2026

Cineverse ( ($CNVS) ) has shared an announcement. On April 27, 2026, Cineverse Corp. entered into an exchange agreement with preferred shareholder ...

Cineverse Announces Preferred Stock Exchange for Common Shares

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on April 28 and set a price target of CHF135.00. The company’s shares clo...

Novartis AG (NOVN) Gets a Buy from Kepler Capital

Goldman Sachs analyst James Quigley maintained a Sell rating on Novartis AG today and set a price target of CHF106.00. According to TipRanks, Quigl...

Goldman Sachs Sticks to Its Sell Rating for Novartis AG (NOVN)

In a report released yesterday, Elmar Kraus from DZ BANK AG maintained a Hold rating on Novartis AG. The company’s shares closed yesterday at CHF11...

Novartis AG (NOVN) Gets a Hold from DZ BANK AG

Cineverse ( ($CNVS) ) has provided an update. On April 15, 2026, Cineverse announced that Sean McCabe will become its Chief Financial Officer, effe...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$148.08	-1.13%	829.34K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$148.08	-1.1%	829.34K
3
4
5
6

NVS

NVS

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel